Clinicopathologic features and prognostic factors of 205 patients with pretreated metastatic breast cancer
10.3969/j.issn.1000-8179.20140428
- VernacularTitle:205例初治转移性乳腺癌的临床病理特点和生存分析
- Author:
Fang WANG
;
Chunfang HAO
;
Yongsheng JIA
;
Xiaodong LIU
;
Zhongsheng TONG
- Publication Type:Journal Article
- Keywords:
breast cancer;
metastasis;
prognosis
- From:
Chinese Journal of Clinical Oncology
2014;(17):1103-1107
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the prognostic factors in patients with metastatic breast cancer (MBC). Methods:A total of 205 patients with pretreated MBC were included in this study. These patients were admitted to the Tianjin Medical University Cancer Insti-tute&Hospital and had undergone radical surgery of breast cancer between January 2008 and December 2010. The clinicopathologic information of the patients was collected in this retrospective analysis. Results: The median overall survival of the patients was 32 months (1 month to 132 months). Luminal A, Luminal B, HER-2 overexpression, and triple-negative patients had a median overall sur-vival of 36 months (4 months to 132 months), 32 months (7 months to 122 months), 29 months (1 month to 85 months), and 24 months (1 month to 98 months), respectively. Univariate analysis showed that lymph node metastases, clinical stage, molecular type, visceral disease, first multiple metastatic sites, and shorter metastasis-free interval were significantly associated with poor outcomes. In multivar-iate analysis, lymph node metastases, clinical stage, molecular type, visceral metastasis, and the number of first metastatic sites were significant predictors of patient survival. Conclusion:Lymph node metastasis, clinical stage, triple-negative breast cancer, and visceral metastasis were used as independent poor prognostic indicators for survival in patients. Results of this study may assist physicians in evaluating the survival potential and determining the appropriate therapeutic strategy for MBC patients.
